Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease

Detalhes bibliográficos
Autor(a) principal: Oliveira, Camila Maria de
Data de Publicação: 2023
Outros Autores: Leotti, Vanessa Bielefeldt, Cappelli, Amanda Henz, Rocha, Anastácia Guimarães, Ecco, Gabriela, Bolzan, Gabriela, Kersting, Nathália, Pereira, Maria Luiza Saraiva, Jardim, Laura Bannach
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFRGS
Texto Completo: http://hdl.handle.net/10183/256722
Resumo: Background: Little is known about preclinical stages of Machado-Joseph disease, a polyglutamine disorder characterized by progressive adult-onset ataxia. Objective: We aimed to describe the longitudinal progression of clinical and oculomotor variables in the preataxic phase of disease. Methods: Carriers and noncarriers were assessed at three visits. Preataxic carriers (Scale for Assessment and Rating of Ataxia score < 3) expected to start ataxia in ≤4 years were considered near onset (PAN). Progressions of ataxic and preataxic carriers, considering status at the end of the study, were described according to the start (or its prediction) of gait ataxia (TimeToAfterOnset) and according to the study time. Results: A total of 35 ataxics, 38 preataxics, and 22 noncarriers were included. The “TimeToAfterOnset” timeline showed that Neurological Examination Scale for Spinocerebellar Ataxias (NESSCA; effect size, 0.09), Inventory of Non-Ataxia Symptoms (INAS0.07), and the vestibulo-ocular reflex gain (0.12) progressed in preataxic carriers, and that most slopes accelerate in PAN, turning similar to those of ataxics. In the study time, NESSCA (1.36) and vertical pursuit gain (1.17) significantly worsened in PAN, and 6 of 11 PANs converted to ataxia. For a clinical trial with 80% power and 2-year duration, 57 PANs are needed in each study arm to detect a 50% reduction in the conversion rate. Conclusions: NESSCA, INAS, vestibulo-ocular reflex, and vertical pursuit gains significantly worsened in the preataxic phase. The “TimeToAfterOnset” timeline unveiled that slopes of most variables are small in preataxics but increase and reach the ataxic slopes from 4 years before the onset of ataxia. For future trials in preataxic carriers, we recommend recruiting PANs and using the conversion rate as the primary outcome. © 2022 International Parkinson and Movement Disorder Society.
id UFRGS-2_e570acbe3b1e178412c4fd340dc57260
oai_identifier_str oai:www.lume.ufrgs.br:10183/256722
network_acronym_str UFRGS-2
network_name_str Repositório Institucional da UFRGS
repository_id_str
spelling Oliveira, Camila Maria deLeotti, Vanessa BielefeldtCappelli, Amanda HenzRocha, Anastácia GuimarãesEcco, GabrielaBolzan, GabrielaKersting, NatháliaPereira, Maria Luiza SaraivaJardim, Laura Bannach2023-04-05T03:47:53Z20231531-8257http://hdl.handle.net/10183/256722001165535Background: Little is known about preclinical stages of Machado-Joseph disease, a polyglutamine disorder characterized by progressive adult-onset ataxia. Objective: We aimed to describe the longitudinal progression of clinical and oculomotor variables in the preataxic phase of disease. Methods: Carriers and noncarriers were assessed at three visits. Preataxic carriers (Scale for Assessment and Rating of Ataxia score < 3) expected to start ataxia in ≤4 years were considered near onset (PAN). Progressions of ataxic and preataxic carriers, considering status at the end of the study, were described according to the start (or its prediction) of gait ataxia (TimeToAfterOnset) and according to the study time. Results: A total of 35 ataxics, 38 preataxics, and 22 noncarriers were included. The “TimeToAfterOnset” timeline showed that Neurological Examination Scale for Spinocerebellar Ataxias (NESSCA; effect size, 0.09), Inventory of Non-Ataxia Symptoms (INAS0.07), and the vestibulo-ocular reflex gain (0.12) progressed in preataxic carriers, and that most slopes accelerate in PAN, turning similar to those of ataxics. In the study time, NESSCA (1.36) and vertical pursuit gain (1.17) significantly worsened in PAN, and 6 of 11 PANs converted to ataxia. For a clinical trial with 80% power and 2-year duration, 57 PANs are needed in each study arm to detect a 50% reduction in the conversion rate. Conclusions: NESSCA, INAS, vestibulo-ocular reflex, and vertical pursuit gains significantly worsened in the preataxic phase. The “TimeToAfterOnset” timeline unveiled that slopes of most variables are small in preataxics but increase and reach the ataxic slopes from 4 years before the onset of ataxia. For future trials in preataxic carriers, we recommend recruiting PANs and using the conversion rate as the primary outcome. © 2022 International Parkinson and Movement Disorder Society.application/pdfengMovement disorders. New York. Vol. 38, no. 1 (Jan. 2023), p. 26-34Doença de Machado-JosephBiomarcadoresMovimentos ocularesProgressão da doençaSpinocerebellar ataxia type 3BiomarkersPre-ataxic periodProgression of clinical and eye movement markers in preataxic carriers of Machado-Joseph DiseaseEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001165535.pdf.txt001165535.pdf.txtExtracted Texttext/plain45958http://www.lume.ufrgs.br/bitstream/10183/256722/2/001165535.pdf.txtf8516bcb1efe96afe5fc0e15116b0b6fMD52ORIGINAL001165535.pdfTexto completo (inglês)application/pdf1120543http://www.lume.ufrgs.br/bitstream/10183/256722/1/001165535.pdffc099f90c460c5f96e81b3b815e065cfMD5110183/2567222023-07-28 03:34:55.842768oai:www.lume.ufrgs.br:10183/256722Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-07-28T06:34:55Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.pt_BR.fl_str_mv Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
title Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
spellingShingle Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
Oliveira, Camila Maria de
Doença de Machado-Joseph
Biomarcadores
Movimentos oculares
Progressão da doença
Spinocerebellar ataxia type 3
Biomarkers
Pre-ataxic period
title_short Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
title_full Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
title_fullStr Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
title_full_unstemmed Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
title_sort Progression of clinical and eye movement markers in preataxic carriers of Machado-Joseph Disease
author Oliveira, Camila Maria de
author_facet Oliveira, Camila Maria de
Leotti, Vanessa Bielefeldt
Cappelli, Amanda Henz
Rocha, Anastácia Guimarães
Ecco, Gabriela
Bolzan, Gabriela
Kersting, Nathália
Pereira, Maria Luiza Saraiva
Jardim, Laura Bannach
author_role author
author2 Leotti, Vanessa Bielefeldt
Cappelli, Amanda Henz
Rocha, Anastácia Guimarães
Ecco, Gabriela
Bolzan, Gabriela
Kersting, Nathália
Pereira, Maria Luiza Saraiva
Jardim, Laura Bannach
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira, Camila Maria de
Leotti, Vanessa Bielefeldt
Cappelli, Amanda Henz
Rocha, Anastácia Guimarães
Ecco, Gabriela
Bolzan, Gabriela
Kersting, Nathália
Pereira, Maria Luiza Saraiva
Jardim, Laura Bannach
dc.subject.por.fl_str_mv Doença de Machado-Joseph
Biomarcadores
Movimentos oculares
Progressão da doença
topic Doença de Machado-Joseph
Biomarcadores
Movimentos oculares
Progressão da doença
Spinocerebellar ataxia type 3
Biomarkers
Pre-ataxic period
dc.subject.eng.fl_str_mv Spinocerebellar ataxia type 3
Biomarkers
Pre-ataxic period
description Background: Little is known about preclinical stages of Machado-Joseph disease, a polyglutamine disorder characterized by progressive adult-onset ataxia. Objective: We aimed to describe the longitudinal progression of clinical and oculomotor variables in the preataxic phase of disease. Methods: Carriers and noncarriers were assessed at three visits. Preataxic carriers (Scale for Assessment and Rating of Ataxia score < 3) expected to start ataxia in ≤4 years were considered near onset (PAN). Progressions of ataxic and preataxic carriers, considering status at the end of the study, were described according to the start (or its prediction) of gait ataxia (TimeToAfterOnset) and according to the study time. Results: A total of 35 ataxics, 38 preataxics, and 22 noncarriers were included. The “TimeToAfterOnset” timeline showed that Neurological Examination Scale for Spinocerebellar Ataxias (NESSCA; effect size, 0.09), Inventory of Non-Ataxia Symptoms (INAS0.07), and the vestibulo-ocular reflex gain (0.12) progressed in preataxic carriers, and that most slopes accelerate in PAN, turning similar to those of ataxics. In the study time, NESSCA (1.36) and vertical pursuit gain (1.17) significantly worsened in PAN, and 6 of 11 PANs converted to ataxia. For a clinical trial with 80% power and 2-year duration, 57 PANs are needed in each study arm to detect a 50% reduction in the conversion rate. Conclusions: NESSCA, INAS, vestibulo-ocular reflex, and vertical pursuit gains significantly worsened in the preataxic phase. The “TimeToAfterOnset” timeline unveiled that slopes of most variables are small in preataxics but increase and reach the ataxic slopes from 4 years before the onset of ataxia. For future trials in preataxic carriers, we recommend recruiting PANs and using the conversion rate as the primary outcome. © 2022 International Parkinson and Movement Disorder Society.
publishDate 2023
dc.date.accessioned.fl_str_mv 2023-04-05T03:47:53Z
dc.date.issued.fl_str_mv 2023
dc.type.driver.fl_str_mv Estrangeiro
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10183/256722
dc.identifier.issn.pt_BR.fl_str_mv 1531-8257
dc.identifier.nrb.pt_BR.fl_str_mv 001165535
identifier_str_mv 1531-8257
001165535
url http://hdl.handle.net/10183/256722
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.pt_BR.fl_str_mv Movement disorders. New York. Vol. 38, no. 1 (Jan. 2023), p. 26-34
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRGS
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Repositório Institucional da UFRGS
collection Repositório Institucional da UFRGS
bitstream.url.fl_str_mv http://www.lume.ufrgs.br/bitstream/10183/256722/2/001165535.pdf.txt
http://www.lume.ufrgs.br/bitstream/10183/256722/1/001165535.pdf
bitstream.checksum.fl_str_mv f8516bcb1efe96afe5fc0e15116b0b6f
fc099f90c460c5f96e81b3b815e065cf
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv
_version_ 1798487553855193088